School of Medicine


Showing 1-50 of 134 Results

  • Ranjana Advani

    Ranjana Advani

    Saul A. Rosenberg, MD, Professor of Lymphoma

    Current Research and Scholarly Interests Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

    The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

  • Ash A. Alizadeh, MD/PhD

    Ash A. Alizadeh, MD/PhD

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

    Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

  • Douglas W. Blayney

    Douglas W. Blayney

    Professor of Medicine (Oncology) at the Stanford University Medical Center

    Current Research and Scholarly Interests Improving the quality of cancer care at Stanford, in our network of care, and nationally

  • Nam Quoc Bui

    Nam Quoc Bui

    Clinical Assistant Professor, Medicine - Oncology

    Bio Dr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in the Sarcoma and Developmental Therapeutics programs. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies.

  • Robert W. Carlson

    Robert W. Carlson

    Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus

    Current Research and Scholarly Interests Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.

  • Jennifer Caswell-Jin

    Jennifer Caswell-Jin

    Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

    Current Research and Scholarly Interests My research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.

  • Christopher T Chen, MD

    Christopher T Chen, MD

    Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

    Bio Dr. Chen is a board-certified, fellowship-trained specialist in oncology and hematology. He is also an Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

    Dr. Chen delivers comprehensive, compassionate care for patients in need of early drug development clinical trials and patients with gastrointestinal cancers. As a researcher, he leads the early drug development group and studies how tumor heterogeneity limits the clinical benefit of anticancer therapies in order to accelerate development of novel therapeutic strategies. Dr. Chen’s work has appeared in the New England Journal of Medicine, JAMA, Journal of Clinical Oncology, Science Advances, Journal of Oncology Practice, and Health Services Research.

    Dr. Chen attended Harvard College, where he graduated summa cum laude and Phi Beta Kappa in molecular biology. He went to medical school at Washington University in St. Louis on a full-tuition merit scholarship, graduating with Alpha Omega Alpha honors, and did his residency training in internal medicine at Massachusetts General Hospital and hematology/oncology fellowship in the combined Harvard Dana-Farber Cancer Institute/Massachusetts General Hospital program. As a fellow, he received the NIH T-32 Ruth L. Kirchstein-National Service Research Award in Cancer Biology for his work exploring the molecular structure of metastatic solid tumors.

    Dr. Chen is a member of the American Society of Clinical Oncology and European Society for Medical Oncology. He is an associate member of the American Association for Cancer Research.

  • Curtis R. Chong, MD, PhD, MPhil, FACP

    Curtis R. Chong, MD, PhD, MPhil, FACP

    Clinical Assistant Professor, Medicine - Oncology

    Bio Dr. Chong was recruited to Stanford from the Memorial Sloan Kettering (MSK) Cancer Center, where he led MSK's launch of the early drug development and immunotherapy clinical trials program in New Jersey. At MSK, Dr. Chong was a member of the gastrointestinal oncology service and was one of two MSK physicians in New Jersey who specialized in treating melanoma. Prior to joining MSK, Dr. Chong was a member of the thoracic oncology service at the Dana-Farber Cancer Institute and an attending physician at the Massachusetts General Hospital and Brigham and Women's Hospital, all ailiates of Harvard Medical School.

    Dr. Chong completed his categorical residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, his oncology fellowship at the Dana-Farber Cancer Institute, and is board-certified in internal medicine and medical oncology. He has received research support from the American Society of Clinical Oncology (Young Investigator Award), Uniting Against Lung Cancer, and the American Cancer Society. Dr. Chong has been published in the New England Journal of Medicine, Nature, Nature Medicine, Nature Chemical Biology, JAMA Oncology, and his research on drug discovery has been featured in the New York Times and Popular Science.

    Born and raised in Honolulu where he attended public schools, Dr. Chong sang in the Honolulu Boy Choir, and was the 1993 Honolulu Star Bulletin Newspaper Boy of the Year. He received his A.B. in biochemical sciences from Harvard University magna cum laude followed by an M.Phil. in Chemistry with Sir Alan Fersht at the University of Cambridge (Emmanuel College). He then received his MD and PhD in pharmacology from The Johns Hopkins University School of Medicine.

    An intrepid traveler and avid long-distance runner, Dr. Chong has visited 54 countries and completed 126 marathons in all 50 states, 18 countries, and 6 on continents.

  • Gilbert Chu

    Gilbert Chu

    Professor of Medicine (Oncology) and of Biochemistry

    Current Research and Scholarly Interests After shuttering the wet lab, we have focused on: a point-of-care device to measure blood ammonia and prevent brain damage; a human protein complex that juxtaposes and joins DNA ends for repair and V(D)J recombination; and strategies for teaching students and for reducing selection bias in educational programs.

  • Michael F. Clarke, M.D.

    Michael F. Clarke, M.D.

    Karel H. and Avice N. Beekhuis Professor in Cancer Biology

    Current Research and Scholarly Interests Dr. Clarke maintains a laboratory focused on two areas of research: i) the control of self-renewal of normal stem cells and diseases such as cancer and hereditary diseases; and ii) the identification and characterization of cancer stem cells. His laboratory is investigating how perturbations of stem cell regulatory machinery contributes to human disease. In particular, the laboratory is investigating epigenetic regulators of self renewal, the process by which stem cells regenerate themselves.

  • Christina Curtis

    Christina Curtis

    Associate Professor of Medicine (Oncology) and of Genetics

    Current Research and Scholarly Interests The Curtis laboratory is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.

  • Millie Das

    Millie Das

    Clinical Associate Professor, Medicine - Oncology

    Bio Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.

  • George Duran

    George Duran

    Cancer Biologist and Laboratory Manager, Medicine - Med/Oncology

    Current Role at Stanford Cancer biologist specializing in the development of novel chemotherapeutic agents and in mechanisms of drug resistance. Current research ranges from molecular studies to further understand the heterogeneity of T-cell lymphomas, to translational studies of molecular determinants of therapeutic response, and clinical trials that use the body’s immune system to fight cancer cells.

    Original research contributions have resulted in the authorship of over eighty publications.

  • Alice C. Fan

    Alice C. Fan

    Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology at the Stanford University Medical Center

    Current Research and Scholarly Interests Dr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.

  • Dean W. Felsher

    Dean W. Felsher

    Professor of Medicine (Oncology) and of Pathology

    Current Research and Scholarly Interests My laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation.

  • George A. Fisher Jr.

    George A. Fisher Jr.

    Colleen Haas Chair in the School of Medicine

    Current Research and Scholarly Interests Clinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.

  • Jessica Foran, MSN, NP, RN, ANP-BC, WHNP-BC

    Jessica Foran, MSN, NP, RN, ANP-BC, WHNP-BC

    Affiliate, Medicine - Med/Oncology

    Bio Jessica Foran, MSN, NP, RN, ANP-BC, WHNP-BC is an advanced practice provider who specializes in breast medical oncology at the Stanford Women's Cancer Center. She graduated with her Adult Health Nurse Practitioner (ANP) and Women's Health Nurse Practitioner (WHNP) degrees from MGH Institute of Health Professions and her Bachelors of Science in Nursing (BSN) degree from Johns Hopkins University School of Nursing. Jessica Foran has special interest in breast oncology, clinical research, survivorship, and reproductive health.

  • James Ford

    James Ford

    Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

    Current Research and Scholarly Interests Mammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.

  • Kristen N Ganjoo

    Kristen N Ganjoo

    Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

    Current Research and Scholarly Interests Giant cell tumor of the bone
    Gastrointestinal stromal tumors
    Soft tissue sarcoma
    Osteosarcoma

  • Joshua Gruber

    Joshua Gruber

    Instructor, Medicine - Oncology

    Bio Dr. Joshua Gruber is an Instructor of Medicine in the division of Medical Oncology at Stanford University Medical Center. He received his Bachelors of Arts, Summa Cum Laude, in biochemistry and physics from the University of Pennsylvania in 2001. He then graduated from the Medical Scientist Training Program at the University of Pennsylvania where he performed doctoral studies in cancer biology and biochemistry. He completed internship and residency in Internal Medicine at Stanford, then was a Clinical Fellowship in Medical Oncology and also a Postdoctoral Fellow in Genetics at Stanford, working in the laboratory of Michael Snyder on integrative genomics of hereditary breast cancer. He is currently has a clinical focus on treating patients with metastatic breast cancer and triple-negative breast cancer and conducts clinical trials on novel therapeutics for these diseases. His laboratory research interests include the molecular biology of breast cancer initiation, the intersection of tumor immunology with cancer growth pathways and the development of molecular tools to interrogate neoplastic tissues.

  • Neel K. Gupta

    Neel K. Gupta

    Clinical Assistant Professor, Medicine - Oncology

    Current Research and Scholarly Interests I have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.

  • Gregory M. Heestand, MD

    Gregory M. Heestand, MD

    Clinical Associate Professor, Medicine - Oncology

    Bio Dr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He currently serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He also collaborates with campus laboratories to help develop new biomarker and treatment technologies. Dr. Heestand is a member of the ECOG-ACRIN gastrointestinal committee and serves as a representative to the NCI Hepatobiliary Task Force. He is also the director of the Stanford Medical Oncology Fellowship Program.

    Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.

    Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read.

  • Christian Hoerner

    Christian Hoerner

    Basic Life Res Scientist, Medicine - Med/Oncology

    Current Role at Stanford Staff Scientist and Lab Manager, Alice Fan Lab

  • Sandra Horning

    Sandra Horning

    Professor of Medicine, Emerita

    Current Research and Scholarly Interests Clinical Interests: Hodgkin's disease and non-Hodgkin's lymphoma. Research Interests: clinical trials in Hodgkin's disease and malignant lymphoma including high dose therapy and autografting, complications of cytotoxic therapy, novel therapeutics, and clinicopathologic correlations.

  • Robert Hsieh

    Robert Hsieh

    Adjunct Clinical Assistant Professor, Medicine - Oncology

    Bio Robert W. Hsieh, M.D. Ph.D. is a medical oncologist who specializes in the treatment of prostate cancer, bladder cancer, kidney (renal) cancer and testicular cancer as a member of Stanford's multi-disciplinary Urologic Cancer Program. Dr. Hsieh obtained his M.D. and Ph.D. degrees at the University of Chicago (Pritzker School of Medicine) and subsequently came to Stanford to complete his Internal Medicine residency and Hematology and Oncology fellowship training (with a clinical focus on genitourinary cancers).

    Dr. Hsieh has also had extensive experience in basic lab research (cancer stem cells, target identification and validation, pre-clinical drug discovery) having done post-doctoral work in the Clarke Lab in the Institute for Stem Cell Biology and Regenerative Medicine. He is currently involved in early phase clinical trials in immuno-oncology in industry.

  • Haruka Itakura

    Haruka Itakura

    Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

    Bio Dr. Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine and practicing oncologist at the Stanford Cancer Center with background in biomedical informatics. She is a physician-scientist whose research mission is to drive medical advances at the intersection of cancer and data science research. Specifically, she aims to innovate state-of-the-art technologies to extract clinically useful knowledge from heterogeneous multi-scale biomedical data to improve diagnostics and therapeutics in cancer. She is a board-certified hematologist-oncologist and informaticist with specialized training in basic science, health services, and translational research. Her clinical background in oncology and PhD training in Biomedical Informatics position her to develop and apply data science methodologies on heterogeneous, multi-scale cancer data to extract actionable knowledge that can improve patient outcomes. Her ongoing research to develop and apply cutting-edge knowledge and skills to pioneer new robust methodologies for analyzing cancer big data is being supported by an NIH K01 Career Development Award in Biomedical Big Data Science. Her research focuses on developing and applying machine learning frameworks and radiogenomic approaches for the integrative analysis of heterogeneous, multi-scale data to accelerate discoveries in cancer diagnostics and therapeutics. Projects include prediction modeling of survival and treatment response, biomarker discovery, cancer subtype discovery, and identification of new therapeutic targets.

Latest information on COVID-19